



3-3-04 Impe

1635

Docket No: AM100013
Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor of Application of: C. SATISHCHANDRAN and Catherine PATCHUK
Application No.: 10/009,134 Group Art No.: 1635
Filed: October 20, 2002 Examiner: Not Yet Assigned
For: METHOD AND COMPOSITIONS FOR INHIBITING THE FUNCTION
OF POLYNUCLEOTIDE SEQUENCES
Confirmation No.: 5538
Customer Number: 25291

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EU673381385US addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

March 2, 2004
Date

J. Darrell Fontenot
J. Darrell Fontenot

2. Identification of Time of Filing

This Information Disclosure Statement

- a. ☐ is filed within three months of the filing date of the application.
- b. ☒ is filed before the mailing date of a first Office Action on the merits.
- c. ☐ is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
- d. ☐ is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p).
- e. ☐ is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).

3. ☐ Certification under 37 CFR 1.97(e) and 1.704(d)
The undersigned attorney certifies

- a. ☐ that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement.
- c. ☐ The undersigned attorney certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.

☒ Newly Cited Information
A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed, except that no copy of a pending U.S. application is enclosed, and if this patent application was filed or entered the national stage after June 30, 2003, no copy of a U.S. patent or U.S. patent application publication is enclosed.

☐ Previously Cited Information
No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120.

Prior application is Application Number _____, filed on _____ of _____ for _____

- ☐ Concise Explanation
Documents cited above which are not in the English Language
- a. ☐ have been explained in the specification.
- b. ☐ have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.

Form PTO-1449 is enclosed in duplicate.

- ☐ Fees
- ☐ Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00


Method of Payment of Fees:

Charge Deposit Account No. 01-1425 in the amount of \$0.00

A duplicate of this statement is enclosed.

Instructions as to Overpayment/Underpayment:

Credit any overpayment and charge any underpayment to Deposit Account No. 01-1425.



J. Darrell Fontenot
Attorney for Applicants
Reg. No. 46,705

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940
Tel. No. (845) 602-3144

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Application Number				10/009,134	
Filing Date				10/20/2002	
First Named Inventor				C. Satishchandran	
Group Art Unit				1635	
Examiner Name					
Attorney Docket Number				AM100013	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document Number (If known)	Kind Code (If Known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US4891315A		Watson, et al.	01-02-1990	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Office	Number	Kind Code (If Known)	Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	2.	WO	95/27783A		Joshi-Sukhwai, Sadna	10-19-1995		<input type="checkbox"/>
	3.	WO	97/34638A		The Regents of the University of California	09-25-1997		<input type="checkbox"/>
	4.	WO	97/07825A		The Regents of the University of Colorado	06-03-1997		<input type="checkbox"/>
	5.	WO	98/05770A		Werner, Dieter, et al.	12-02-1998		<input type="checkbox"/>
	6.	WO	99/53050A		Commonwealth Scientific and Industrial Research Organization	10-21-1999		<input type="checkbox"/>
	7.	WO	00/44914A		Medical College of Georgia Research Institute, Inc.	03-08-2000		<input type="checkbox"/>


OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	8.	JAEGER, J.A., ET AL; "Improved Predictions of Secondary Structures for RNA"; Proceedings of the National Academy of Sciences of the United States; Vol. 86, No. 20; Pgs. 7706-7710; 1989.	<input type="checkbox"/>
	9.	NELLEN, W., ET AL.; "What Makes an mRNA Anti-Sense-itive?"; TIBS Trends in Biochemical Sciences; Vol. 18, No. 11; Pgs. 419-423; November 1, 1993.	<input type="checkbox"/>
	10.	MIKITA, T., ET AL; "Effects of Arabinosylcytosine-Substituted DNA on DNA/RNA Hybrid Stability and Transcription by T7 RNA Polymerase"; Biochemistry; Vol. 33; Pgs. 9195-9208; 1994.	<input type="checkbox"/>
	11.	YUKIKO, TONE, ET AL.; "Structure and Chromosomal Location of the Mouse Interleukin-12 P35 and P40 Subunit Genes", European Journal of Immunology; Vol. 26, No. 6; Pgs. 1222-1227; June 1, 1996	<input type="checkbox"/>
	12.	PLAYER, MARK, R., ET AL.; "Targeting HIV mRNA for Degradation: 2,5-A Antisense Chimeras as Potential Chemotherapeutic Agents for AIDS"; Nucleosides & Nucleotides; Vol. 16, No. 7-9; Pgs. 1221-1222; July, 1997.	<input type="checkbox"/>
	13.	JORGENSEN, RICHARD A., ET AL; "An RNA-Based Information Superhighway in Plants"; Science Magazine, Vol. 279; Pgs. 1486-1487; 1998.	<input type="checkbox"/>
	14.	MONTGOMERY, M.K., ET AL.; "Double-Stranded RNA as a Mediator in Sequence-Specific Genetic Silencing and Co-Suppression"; Trends in Genetics; Vol 14, No. 7; Pgs. 255-258; July 1, 1998.	<input type="checkbox"/>
	15.	WATERHOUSE, ET AL.; "Virus Resistance and Gene Silencing in Plants can be Induced by Simultaneous Expression of Sense and Antisense RNA"; Proceedings of the National Academy of Sciences of USA, National Academy of Science; Vol. 95; Pgs. 13959-13964; November, 1998.	<input type="checkbox"/>
	16.	TIMMONS, L.. AND FIRE, A.; "Specific Interference by Ingested dsRNA"; Nature; Vol. 395; Pg. 854; October 29, 1998.	<input type="checkbox"/>
	17.	FIRE, A., ET AL.; "Potent and Specific Genetic Interference by Double-Stranded RNA in Caenorhabditis Elegans"; Nature; Vol. 391; Pgs. 806-810; February 19, 1998.	<input type="checkbox"/>
	18.	BAHRAMIAN, MOHAMMAD B. AND ZARBL, H.; "Transcriptional and Posttranscriptional Silencing of Rodent $\alpha 1(I)$ Collagen by a Homologous Transcriptionally Self-Silenced Transgene"; Molecular and Cellular Biology; Vol. 19, No. 1; Pgs. 274-283; January 1999.	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Application Number				10/009,134	
Filing Date				10/20/2002	
First Named Inventor				C. Satishchandran	
Group Art Unit				1635	
Examiner Name					
Attorney Docket Number				AM100013	
Sheet	2	of	2		



OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T	
	19.	WIANNY, F. AND ZERNICKA-GOETZ, M.; "Specific Interference with Gene Function by Double-Stranded RNA in Early Mouse Development"; Nature Cell Biology; Vol. 2, No. 2; Pgs. 70-75; February, 2000.	<input type="checkbox"/>	
	20.	PARK WEE-SUNG, ET AL.; "Inhibition of HIV-1 Replication by a New Type of Circular Dumbbell RNA/DNA Chimeric Oligonucleotides", Biochemical and Biophysical Research Communications; Vol. 270, No. 3; Pgs. 953-960; April 21, 2000.	<input type="checkbox"/>	
	21.	CAPLEN, N.J., ET AL.; "dsRNA-Mediated Gene Silencing in Cultured Drosophila Cells: A Tissue Culture Model for the Analysis of RNA Interference"; Vol. 252, No. 1-2; Pgs. 95-105; July 11, 2000.	<input type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.